Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial

被引:1
|
作者
Bulpitt, Christopher J. [1 ,2 ]
Webb, Richard [2 ]
Beckett, Nigel [1 ]
Peters, Ruth [1 ]
Cheek, Elizabeth [4 ]
Anderson, Craig [5 ]
Antikainen, Riitta [7 ,8 ]
Staessen, Jan A. [6 ]
Rajkumar, Chakravarthi [2 ,3 ]
机构
[1] Imperial Coll London, Dept Med, London, England
[2] Brighton & Sussex Med Sch, Dept Med, Brighton BN2 5BE, E Sussex, England
[3] Brighton & Sussex Univ Hosp, Dept Elderly Med, Brighton, E Sussex, England
[4] Univ Brighton, Dept Math, Brighton, E Sussex, England
[5] George Inst Global Hlth, Dept Neurol, Sydney, NSW, Australia
[6] Univ Leuven, Dept Med, Leuven, Belgium
[7] Elderly Oulu City Hosp, Div Med Care, Oulu, Finland
[8] Oulu Univ, Inst Hlth Sci Geriatr, Oulu, Finland
关键词
Hypertension in the very elderly; QKD; arterial compliance; vascular stiffness; ambulatory blood pressure; HYVET; CENTRAL BLOOD-PRESSURE; PULSE-WAVE VELOCITY; AMBULATORY MEASUREMENT; KOROTKOFF SOUNDS; KIDNEY-DISEASE; QKD INTERVAL; MORTALITY; AGE; DISTENSIBILITY; POPULATION;
D O I
10.1080/08037051.2016.1219222
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The main Hypertension in the Very Elderly Trial (HYVET) demonstrated a very marked reduction in cardiovascular events by treating hypertensive participants 80 years or older with a low dose, sustained release prescription of indapamide (indapamide SR, 1.5mg) to which was added a low dose of an angiotensin converting enzyme inhibitor in two-thirds of cases (perindopril 2-4mg). This report from the ambulatory blood pressure sub-study investigates whether changes in arterial stiffness and ambulatory blood pressure (BP) could both explain the benefits observed in the main trial. A total of 139 participants were randomized to placebo [67] and to active treatment [72] and had both day and night observations of BP and arterial stiffness as determined from the Q wave Korotkoff diastolic (QKD) interval. The QKD interval was 5.6ms longer (p=0.017) in the actively treated group at night than in the placebo group. This was not true for the more numerous daytime readings so that 24-h results were similar in the two groups. The QKD interval remained longer at night in the actively treated group even when adjusted for systolic pressure, heart rate and height. The reduced arterial stiffness at night may partly explain the marked benefits observed in the main trial.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 35 条
  • [31] Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial
    Zhang, Juan
    Kan, Jing
    Wei, Yongyue
    Zhang, Caojin
    Yang, Zhenwen
    Gu, Heping
    Fan, Fenling
    Gu, Hong
    Wang, Qiguang
    Xie, Dujiang
    Zhang, Gangcheng
    Guo, Xiaomei
    Yin, Yuehui
    Jin, Bowen
    Zhou, Hongmei
    Yang, Ziyang
    Wang, Zhouming
    Xin, Yu
    Zhang, Chen
    Meng, Lili
    Wang, Xiaoyu
    Zhao, Chunxia
    Zhang, Hang
    Yan, Xiaoyan
    Chen, Feng
    Yao, Cheng
    Benza, Raymond L.
    Stone, Gregg W.
    Chen, Shao-Liang
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (08): : 1140 - 1151
  • [32] Treatment Effects of Pulmonary Artery Denervation for Pulmonary Arterial Hypertension Stratified by Reveal Risk Score: Results From PADN-CFDA Trial
    Chen, Shao-Liang
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (04) : S50 - S50
  • [33] The usefulness of a single arm cuff oscillometric method (Arteriograph) to assess changes in central aortic blood pressure and arterial stiffness by antihypertensive treatment: results from the Doxazosin-Ramipril Study
    Jekell, Andreas
    Kahan, Thomas
    BLOOD PRESSURE, 2018, 27 (02) : 88 - 98
  • [34] Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Muntner, Paul
    Davis, Barry R.
    Cushman, William C.
    Bangalore, Sripal
    Calhoun, David A.
    Pressel, Sara L.
    Black, Henry R.
    Kostis, John B.
    Probstfield, Jeffrey L.
    Whelton, Paul K.
    Rahman, Mahboob
    HYPERTENSION, 2014, 64 (05) : 1012 - +
  • [35] Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
    Nakao, Akira
    Hiranuma, Osamu
    Uchino, Junji
    Sakaguchi, Chikara
    Araya, Tomoyuki
    Hiraoka, Noriya
    Ishizuka, Tamotsu
    Takeda, Takayuki
    Kawasaki, Masayuki
    Goto, Yasuhiro
    Imai, Hisao
    Hattori, Noboru
    Nakatomi, Keita
    Uramoto, Hidetaka
    Uryu, Kiyoaki
    Fukuda, Minoru
    Uchida, Yasuki
    Yokoyama, Toshihide
    Akai, Masaya
    Mio, Tadashi
    Nagashima, Seiji
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Mouri, Takako
    Yamada, Tadaaki
    Yoshimura, Kenichi
    Fujita, Masaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 12